Our research brings together more than four decades of ground-breaking research and development on vaccines as well as extensive domestic and international research to combat critical global health issues, such as the threat of drug resistant malaria, antimicrobial resistance, enteric diseases and other tropical and emerging pathogens burdening low resource settings.
Diseases of interest include malaria, Ebola, Zika, and vaccine-preventable infectious diseases such as measles, cholera, typhoid, shigellosis, Escherichia coli diarrhea, influenza and respiratory diseases and others.
For more than 40 years researchers in the Center for Vaccine Development and Global Health have worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s most underserved populations. Our Malaria Research Program is an important component of the CVDGH and performs the crucial work needed to support global malaria eradication.
We are in a unique position where faculty and researchers collaborate across areas in the critical work of antigen discovery, microbial pathogenesis, immunology, and clinical and field research.
We have nearly 40 faculty physicians and scientists who collaborate with other University of Maryland School of Medicine institutes, centers, departments and programs, as well as other schools on campus and research institutions around the globe.
We have created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal Salmonella, shigellosis, Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza and other infectious diseases. Learn more
Our researchers support global malaria eradication efforts and have developed and deployed innovative tools for improved malaria treatment, prevention, and surveillance. In our molecular parasitology and immunology laboratories in Baltimore and at field research sites across Africa and Asia, we lead clinical trials of malaria drugs and vaccines. Learn more
Our accomplished, multidisciplinary team brings extensive clinical research and regulatory experience, including the design and performance of clinical trials in all phase of development and in diverse populations, and the design and execution of human challenge studies. Learn more
Our experts are conducting innovative research into treating antibiotic resistant infections. In addition to our vaccine development and prevention research, our research focuses on life-threating infections such as methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumonia (KB), and Pseudomonas aeruginosa (PA), by among other things targeting the body’s immune response to harmful bacteria.
Our decades of experience in vaccine research and development puts us at the forefront of research into emerging pathogens such as the Zika virus. Our researchers conducted a trial to evaluate the safety of a new Zika vaccine and its ability to generate an immune system response in humans. Our experts also conducted a successful clinical trial of a new Ebola vaccine, carried out in Mali, West Africa and Baltimore.
Our molecular biologists, microbiologists, immunologists, internists, pediatricians, epidemiologists and biostatisticians have worked on projects at several sites in Africa, Asia and other low resources settings to better understand and address disease burden, particularly for those most vulnerable – children under the age of five. In addition to surveillance, our researchers have developed and conducted trials on vaccines and other interventions for these diseases, a leading cause of death.
Through our Vaccine and Treatment Evaluation Unit (VTEU), funded by the National Institute of Allergy and Infectious Diseases (NIAID), our experts have conducted multiple clinical trials of vaccines designed to protect individuals from various strains of the influenza virus. Our research has focused on the efficacy and safety of vaccines for varying age groups such as older adults and efficacy and safety in pregnancy.